Navigation Links
Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
Date:9/2/2008

w therapies that provide rapid onset of predictable effect and are delivered in a patient-friendly, non-invasive manner."

Phase 3 Clinical Trial Design

The AZ-004 clinical trial enrolled 344 schizophrenic patients with acute agitation at 24 U.S. clinical centers. The trial was designed as an in-clinic, multi-center, randomized, double-blind, placebo-controlled study and tested AZ-004 at two dose levels, 5 mg and 10 mg. Patients were eligible to receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status. Only one dose of study drug was allowed during the first 2 hours of the study period.

The primary endpoint for the study was the change from baseline in the PANSS (Positive and Negative Symptom Scale) Excited Component score (also known as PEC score), measured at 2 hours after the first dose. The key secondary endpoint was the Clinical Global Impression-Improvement (CGI-I) score, measured at 2 hours after the first dose. All results were considered statistically significant at the p < 0.05 level, as compared to placebo, and all analyses were made on an intent-to-treat basis. Various additional assessments of a patient's agitation state were conducted at serial time points using the PEC scale over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects were recorded for each patient throughout their 24-hour study period.

Primary Efficacy Endpoint

Both the 5 mg and the 10 mg dose of AZ-004 met the primary endpoint of the clinical trial, showing a statistically significant improvement in the 2-hour post-dose PEC score, compared to placebo.

PEC Scores (Mean Values)

p-Value for Change

from Baseline

Study Arm Baseline 2-Hour Post-Dose vs. Placebo

10 mg AZ-004<
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
2. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
3. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
4. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
5. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Calabar AB Today Announced New Financing for Continuation of the Phase II Program in Patients With Dry Mouth
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Ore. , Aug. 29, 2014 /PRNewswire-iReach/ -- ... Accessory (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today ... voluntary recall to address a potential issue with ... used for the Axilla application of the SAM ...
(Date:8/29/2014)...  A Boston Scientific Corporation (NYSE: ... and preliminary long term stricture resolution of benign ... issue of the peer-reviewed journal, Gastroenterology. ... conducted in 11 countries and five continents, and ... (FCSEMS) after extended indwell (i.e., up to 12 ...
(Date:8/29/2014)... 2014 Medina Medical announced today that Mr. ... the Board of Directors on August 18, 2014. Mr. ... commercialization experience, including over a decade of direct experience ... a Partner of the medical device incubator The Foundry, ... Foundry start-ups. Mr. Engelson previously served as the Chief ...
Breaking Medicine Technology:SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2
... 20 Today, Family Research,Council President Tony Perkins ... Shinya Yamanaka. Thomson, the first to grow human ... in the journals Science,and Cell, respectively, showing that ... human skin cells, without first creating or,destroying human ...
... International,Corporation (Nasdaq: PRXL ), a ... Dr. Victor Kiri, formerly with GlaxoSmithKline,as ... Clinical Research,Services business. Dr. Kiri,s responsibilities ... conduct of comparative observational studies, offering,epidemiological ...
Cached Medicine Technology:PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 2PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 3PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri 4
(Date:8/30/2014)... Acne is a common problem millions of American ... more than a daily nuisance, for some, it can have a ... can even lead to dramatic mood swings and depression. , ... clear up their skin. In some cases, that can make the ... and error, those on a quest for clearer skin can now ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... incretin mimetic claims continue to move forward in U.S. ... issued by AstraZeneca PLC on July 31, 2014, Byetta ... named in 409 product liability claims that allege the ... documents indicate that many of these claims are pending ...
(Date:8/30/2014)... HealthDay Reporter FRIDAY, Aug. 29, ... on for broken bones or other orthopedic trauma shops around ... Less-educated patients and patients who had used narcotic painkillers ... said study lead author Dr. Brent Morris, a shoulder and ... suggests that doctors aren,t talking to one another about the ...
(Date:8/30/2014)... "My wife suffered neck, back and spine injuries ... of two inventors from Bethel, Alaska. "The whiplash contributed ... area. She tried other pillows to little avail. The ... comfort and providing extra sleep." , They created a ... head, neck and back comfortably. This enables the user ...
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... sleep knowing that, at any moment, her fever might ... order to keep me well aware of how she ... developed the TEMP ALARM to continuously monitor a child's ... develops a fever. This ensures that prompt medical care ...
Breaking Medicine News(10 mins):Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3
... poor heart health, how to diagnose disease early and other tips to prolong ... ... a principle cause of death in dogs, affecting more than 10 percent of ... site devoted to this issue - www.yourdogsheart.com - is designed to ...
... method of assessing the quality of phase I ... conferences: EORTC-NCI-AACR (ENA) [1] and American Society of ... (23 October) at the 20th ENA Symposium on ... there is room for improvement and the researchers ...
... ... for hospitals, COLUMBUS, Ga., Oct. 21 As more hospitals ... survey(i) by,insurance provider Aflac finds that 86 percent of nurses say ... determining where,they choose to work, and more than half report they ...
... Vista Partners announced today,that it has updated coverage ... its $8.50 price. "MediciNova recently announced positive,preliminary data ... sizable,percentage of the asthma market potentially resulting in ... Medicinova,s other clinical,candidate, MN-166, is intended for the ...
... 21 Some 2.3 million,children a year, mostly from ... pay for preventive or other medical needs, even though ... a new study supported,by HHS, Agency for Healthcare Research ... of HHS, National Institutes of Health., The new ...
... The fifty-year-old program,s difference: Melting stored fat and increasing ... the body,s metabolism for ... of economic,instability, there is a different type of belt tightening going ... Green Valley Spa,has become the first destination spa in the U.S. ...
Cached Medicine News:Health News:New Web Site Devoted to Canine Heart Disease - A Leading Cause of Death in Dogs 2Health News:Assessing the quality of phase I clinical trial abstracts 2Health News:Assessing the quality of phase I clinical trial abstracts 3Health News:Nurses Report Quality Health Benefits Key to Choosing an Employer 2Health News:Vista Partners Updates Coverage on MediciNova Inc. (NASDAQ: MNOV); Maintains $8.50 Price Target 2Health News:More Than 2 Million Children With Insured Parents Are Uninsured; Most Are Low or Middle Income 2Health News:More Than 2 Million Children With Insured Parents Are Uninsured; Most Are Low or Middle Income 3Health News:Green Valley Spa Now Offers hCG Weight Loss Therapy 2
... an extremely accurate digital A-scan system. The ... probe and fast precise algorithm enables scan ... along the visual axis. The A5500 A-scan ... monitor, built-in thermal printer, 5 different examination ...
... is extremely portable, weighing slightly more than ... system provides a large liquid crystal display. ... noise probe and fast precise algorithm enables ... probe along the visual axis. The Microscan ...
... Accurate, efficient and easy to use. The ... variety of regressive, theoretical, and adaptive IOL ... the patient. Convenient design features improve your ... hands-free operation, audible tone to minimize corneal ...
... Ultrasonic A-Scan offers so many ... package. Besides,its compact and lightweight ... measurement and easy operation.,Furthermore, it ... and manual gate.,NIDEK is proud ...
Medicine Products: